Neovii
Axel Witt, Dr. has extensive experience in the fields of medical affairs and life sciences, currently serving as the International Medical Affairs Manager at Neovii since November 2020. In this role, Axel Witt oversees the implementation of global medical strategies across various therapy areas, including hematology and oncology, while fostering relationships with medical experts and leading clinical trials. Prior to Neovii, Axel Witt was a Postdoctoral Research Scientist at Genentech, focusing on inflammatory diseases and immunology, and held research fellow positions at CECAD Cologne, where projects examined tumor cell adaptations, and at Uniklinik Köln, contributing to a deeper understanding of tumor growth mechanisms. An accomplished academic, Axel Witt holds a PhD in Molecular Biology and Genetics from the University of Cologne and is currently pursuing an Executive MBA at the Quantic School of Business and Technology.
This person is not in the org chart
This person is not in any teams
Neovii
Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology. Our lead product, Grafalon®, has been used for over 30 years to treat patients and is available in more than 40 countries world wide. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.